Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201678 | 0.86 | PABPC1 (0.46) | — | |
| SCHEMBL14994233 | 0.82 | HDAC1 (0.41) | HDAC6HDAC1HDAC10HDAC8HDAC2 | |
| SCHEMBL9657474 | 0.76 | KDM4E (0.46) | — | |
| SCHEMBL14994242 | 0.75 | HDAC6 (0.49) | HDAC6HDAC1HDAC10HDAC8HDAC2 | |
| SCHEMBL14994865 | 0.74 | HDAC6 (0.50) | HDAC6HDAC1HDAC10HDAC8HDAC2 | |
| SCHEMBL16201684 | 0.69 | CDK5 (0.45) | HDAC6 | |
| SCHEMBL14994765 | 0.69 | PABPC1 (0.49) | — | |
| SCHEMBL14994618 | 0.69 | HDAC6 (0.41) | HDAC6HDAC1HDAC8HDAC11 | |
| SCHEMBL14994323 | 0.69 | HDAC6 (0.42) | HDAC6HDAC1HDAC10HDAC8HDAC2 | |
| SCHEMBL14994775 | 0.68 | HDAC6 (0.40) | HDAC6HDAC1HDAC10HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345905-B2 | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | BETA PHARMA CANADA INC. (CA) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | HDAC6, HDAC1, HDAC7 | HDAC6 1/4885HDAC1 2/4885HDAC10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.